Published in Breast Cancer Res on September 22, 2004
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A (2010) 1.71
The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A (2006) 1.61
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst (2008) 1.61
Insights into the pharmacological relevance of lysophospholipid receptors. Br J Pharmacol (2012) 1.31
Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets (2008) 1.27
ATX-LPA receptor axis in inflammation and cancer. Cell Cycle (2009) 1.27
Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer (2010) 1.25
Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol (2014) 1.21
Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J (2008) 1.00
Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells. World J Gastroenterol (2005) 0.98
The absence of LPA receptor 2 reduces the tumorigenesis by ApcMin mutation in the intestine. Am J Physiol Gastrointest Liver Physiol (2010) 0.97
MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells. Gastroenterology (2010) 0.95
Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactions. Biochim Biophys Acta (2008) 0.95
G-protein-coupled receptor signaling and polarized actin dynamics drive cell-in-cell invasion. Elife (2014) 0.92
The gep proto-oncogene Gα13 mediates lysophosphatidic acid-mediated migration of pancreatic cancer cells. Pancreas (2013) 0.89
LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J Cell Physiol (2011) 0.88
CARMA3: A novel scaffold protein in regulation of NF-κB activation and diseases. World J Biol Chem (2010) 0.86
Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. J Biol Chem (2012) 0.86
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol (2011) 0.85
Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis. Mol Cancer Res (2014) 0.84
Submucosal connective tissue-type mast cells contribute to the production of lysophosphatidic acid (LPA) in the gastrointestinal tract through the secretion of autotaxin (ATX)/lysophospholipase D (lysoPLD). Virchows Arch (2007) 0.79
Lysophosphatidic Acid Up-Regulates Hexokinase II and Glycolysis to Promote Proliferation of Ovarian Cancer Cells. Neoplasia (2015) 0.78
TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation. Cell Discov (2016) 0.78
Potential biomarkers in the sera of breast cancer patients from bahawalpur, pakistan. Biomark Cancer (2012) 0.77
Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers. Clin Exp Med (2014) 0.77
Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo. J Biomed Res (2015) 0.77
Loss of the BRCA1-interacting helicase BRIP1 results in abnormal mammary acinar morphogenesis. PLoS One (2013) 0.76
Lysophosphatidic acid (LPA) signaling in human and ruminant reproductive tract. Mediators Inflamm (2014) 0.75
Analysis of glycero-lysophospholipids in gastric cancerous ascites. J Lipid Res (2017) 0.75
Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer. Oncogene (2015) 0.75
Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation. Cancer Prev Res (Phila) (2016) 0.75
Expression of lysophosphatidic acid receptors and local invasiveness and metastasis in Chinese pancreatic cancers. Curr Oncol (2012) 0.75
Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia. PLoS One (2016) 0.75
LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. BMC Cancer (2016) 0.75
The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer (2003) 6.70
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA (1998) 5.09
Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. N Engl J Med (1996) 3.79
Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst (1990) 3.02
Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA (1999) 2.80
Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem (1995) 2.76
Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A (2000) 2.60
Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem (1998) 2.49
Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem (1999) 2.44
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 2.27
Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J (1998) 2.20
Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta (2002) 2.18
Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res (1999) 2.17
Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol Cell Biol (2002) 2.06
Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat (1998) 1.77
Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci (2000) 1.67
Insulin resistance and breast-cancer risk. Int J Cancer (1992) 1.57
Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA (2002) 1.51
Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer (1993) 1.47
Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res (2001) 1.45
Breast cancer: weighing the evidence for a promoting role of dietary fat. J Natl Cancer Inst (1997) 1.42
Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res (1999) 1.39
Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol (1999) 1.26
Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology (2002) 1.23
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res (2002) 1.22
The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem (2003) 1.18
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res (1999) 1.18
Epidemiology of breast cancer. Eur J Cancer Prev (1995) 1.18
Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer (2001) 1.17
Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol (2001) 1.15
Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem (2001) 1.14
Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Cancer Res (1999) 1.13
Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res (1999) 1.10
Insulin induces heterologous desensitization of G-protein-coupled receptor and insulin-like growth factor I signaling by downregulating beta-arrestin-1. Mol Cell Biol (2002) 1.05
Lysophosphatidic acid: receptors, signaling and survival. Cell Mol Life Sci (2000) 1.00
The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol (1997) 1.00
The insulin-like growth factors (IGF) and IGF type I receptor during postnatal growth of the murine mammary gland: sites of messenger ribonucleic acid expression and potential functions. Endocrinology (1999) 0.97
Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett (2003) 0.96
Lysophospholipid mediators of immunity and neoplasia. Biochim Biophys Acta (2002) 0.92
Adiposity as a risk determinant for postmenopausal breast cancer. Int J Obes Relat Metab Disord (2000) 0.89
Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management. Prostaglandins Other Lipid Mediat (2001) 0.87
Potentiation of Rho-A-mediated lysophosphatidic acid activity by hyperinsulinemia. J Biol Chem (2000) 0.87
Comparative study of blood insulin levels in breast and endometrial cancer patients. Neoplasma (1997) 0.79
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature (2005) 3.35
Modified double-K method for intraocular lens power calculation after excimer laser corneal refractive surgery. J Cataract Refract Surg (2013) 3.29
The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell (2013) 3.19
Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A (2002) 3.01
Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem (2006) 2.79
Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res (2004) 2.52
Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem (2002) 2.42
No forward shifting of posterior corneal surface in eyes undergoing LASIK. Ophthalmology (2007) 2.21
Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem (2004) 2.17
Impaired α-TTP-PIPs interaction underlies familial vitamin E deficiency. Science (2013) 2.15
TGFα shedding assay: an accurate and versatile method for detecting GPCR activation. Nat Methods (2012) 2.04
Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med (2012) 2.04
Popliteal arterial aneurysm associated with Klippel-Trénaunay syndrome: case report and literature review. J Vasc Surg (2006) 2.04
Fall prevention using olfactory stimulation with lavender odor in elderly nursing home residents: a randomized controlled trial. J Am Geriatr Soc (2012) 2.03
Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res (2003) 1.99
Subcortical hematoma caused by cerebral amyloid angiopathy: does the first evidence of hemorrhage occur in the subarachnoid space? Neuropathology (2003) 1.99
Structure and function of Zucchini endoribonuclease in piRNA biogenesis. Nature (2012) 1.90
Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol (2003) 1.87
Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut (2007) 1.87
Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol (2011) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res (2003) 1.83
Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res (2007) 1.82
Isolated spontaneous dissection of the splanchnic arteries. J Vasc Surg (2008) 1.79
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer (2010) 1.78
Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab (2012) 1.77
The MAP1-LC3 conjugation system is involved in lipid droplet formation. Biochem Biophys Res Commun (2009) 1.77
Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging (2012) 1.77
Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res (2003) 1.73
The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol (2009) 1.71
Early appendiceal adenocarcinoma. A review of the literature with special reference to optimal surgical procedures. J Gastroenterol (2002) 1.62
Plasma adiponectin and gastric cancer. Clin Cancer Res (2005) 1.62
Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: evidence of epistasis and competitive binding. Hum Mol Genet (2008) 1.60
GPR34 is a receptor for lysophosphatidylserine with a fatty acid at the sn-2 position. J Biochem (2012) 1.60
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med (2013) 1.58
DISC1-NDEL1/NUDEL protein interaction, an essential component for neurite outgrowth, is modulated by genetic variations of DISC1. Hum Mol Genet (2006) 1.58
Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem (2006) 1.55
ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. J Biol Chem (2007) 1.54
The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest (2012) 1.54
Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1. J Lipid Res (2006) 1.52
A missense mutation within the helix initiation motif of the keratin K71 gene underlies autosomal dominant woolly hair/hypotrichosis. J Invest Dermatol (2012) 1.51
A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry (2005) 1.51
Scalp acupuncture effects of stroke studied with magnetic resonance imaging: different actions in the two stroke model rats. Acupunct Med (2009) 1.50
A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. J Biol Chem (2002) 1.49
Autotaxin--an LPA producing enzyme with diverse functions. J Biochem (2010) 1.49
Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest (2004) 1.49
Decrease in membrane phospholipid unsaturation induces unfolded protein response. J Biol Chem (2010) 1.48
Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol (2004) 1.48
LPA-producing enzyme PA-PLA₁α regulates hair follicle development by modulating EGFR signalling. EMBO J (2011) 1.48
Detection of cancer cells in mesenteric vein and peripheral vessels by measuring telomerase activity in patients with colorectal cancer. Surgery (2003) 1.45
Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am J Clin Nutr (2006) 1.45
Impaired efficacy of cough in patients with Parkinson disease. Chest (2003) 1.44
Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J Biol Chem (2003) 1.43
Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol (2004) 1.42
Early gastric cancer shows different associations with adipose tissue volume depending on histological type. Gastric Cancer (2008) 1.42
Ocular integrity after anterior ciliary sclerotomy and scleral ablation by the Er:YAG laser. J Refract Surg (2005) 1.41
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Effect of age on changes in anterior chamber depth and volume after laser in situ keratomileusis. J Cataract Refract Surg (2009) 1.41
Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol (2004) 1.40
Elective colon and rectal surgery differ in risk factors for wound infection: results of prospective surveillance. Ann Surg (2006) 1.39
Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci (2005) 1.38
The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett (2003) 1.38
2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med (2007) 1.37
Emphysematous cholecystitis with massive gas in the abdominal cavity. World J Gastroenterol (2013) 1.36
Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer (2011) 1.35
Activation of mitogen-activated protein kinases by lysophosphatidylcholine-induced mitochondrial reactive oxygen species generation in endothelial cells. Am J Pathol (2006) 1.33
Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie (2010) 1.32
Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res (2006) 1.32
Caenorhabditis elegans mboa-7, a member of the MBOAT family, is required for selective incorporation of polyunsaturated fatty acids into phosphatidylinositol. Mol Biol Cell (2007) 1.31
Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res (2006) 1.30
Risk factors for anastomotic leakage after surgery for colorectal cancer: results of prospective surveillance. J Am Coll Surg (2006) 1.30
Polyacrylamide gel containing egg white as new model for irradiation experiments using focused ultrasound. Ultrasound Med Biol (2004) 1.30
Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol (2007) 1.29